Biotech Values

[bladerunner1717]

re: ARRY

In this trial, ARRY-797 was considered overall to be well-tolerated at the selected dose of 400 mg twice-daily. The most common adverse events observed in patients treated with ARRY-797 were dizziness, diarrhea and nausea, which were mainly mild in severity. ARRY-797 treatment was associated with sporadic, transient increases in creatine kinase and aspartate aminotransferase. Mild prolongations of the QTc interval and sustained decreases in systolic and diastolic blood pressure were also observed.

Isn't the QTc issue a huge red flag? I have osteoarthritis and I'm not sure I'd want to take this drug and ARRY is my second biggest holding. LOLOL The SP is down 12% in AH. (I really think this might be overdone; no one that I know had this drug factored into their valuation models.) Would any BP want to take on this drug?


Bladerunner